Off-Label Testosterone Therapy and Cardiovascular Risk

In 2026, medical researchers published a retrospective cohort study in eBioMedicine detailing the cardiovascular risks associated with off-label testosterone therapy. The research team, led by Hatim Kerniss of the Department of Cardiology at University Heart Centre Frankfurt, analyzed data from men aged 30 to 75 who initiated testosterone treatment. By reviewing de-identified electronic health records from 123 healthcare organizations worldwide, the team identified distinct outcome differences based on diagnostic documentation. The findings highlight an association between treatment initiated without documented evidence of hypogonadism and a higher reported rate of major adverse cardiovascular events.

Proper Documentation Protects Long Term Health

Testosterone replacement therapy represents a significant consideration for men managing their physical health over time. For service members and veterans, maintaining physical capability often brings increased attention to endocrine function and hormone levels. Some patients seek medical interventions for general symptoms without securing a formal diagnosis of low testosterone. This new study underscores the critical necessity of confirming hypogonadism through appropriate clinical evaluation before pursuing any hormone replacement regimen.

Initiating testosterone therapy without documented evidence of a clinical deficiency leaves patients vulnerable to unforeseen medical complications. Seeking safe veteran lifestyle and healthcare resources helps patients make informed decisions about their enduring physical condition. The findings offer a strong reminder that individual clinical evaluation of symptoms remains paramount for safe care. Service members should view this study as a prompt to evaluate their cardiovascular risk and follow up directly with their treating clinician.

Navigating the healthcare system after active duty requires a clear understanding of the risks associated with various medical treatments. The transition to civilian life often involves establishing new routines and finding doctors who understand the physical demands of military service. Integrating safe practices into daily life ensures that underlying conditions receive appropriate clinical attention. Recognizing the importance of documented diagnoses empowers veterans to advocate for safer and more effective treatment plans.

It is important to note that the studied cohort is not military specific. Readers should avoid assuming that the specific numerical effect estimates apply directly to active-duty personnel or veterans. However, the operational takeaway remains highly relevant for those navigating post-service medical care. Men already receiving testosterone should use these findings to initiate a productive conversation with their doctor about long-term cardiovascular monitoring.

Large Scale Data Reveals Cardiovascular Trends

The researchers constructed a substantial dataset to analyze the varying outcomes among testosterone users. Out of 358,957 men who initiated testosterone therapy, the data revealed a significant gap in diagnostic records. According to the medical report, 127,152 of those men had no documented evidence of hypogonadism prior to starting treatment. This indicates that 35.4 percent of the studied population initiated care without a recorded clinical deficiency.

The analysis specifically excluded men with prior testosterone use or those who experienced major cardiovascular or thromboembolic events during the preceding three years. To isolate the variables, the research team utilized propensity-score matching to compare specific patient groups. They successfully matched 113,554 pairs of men with and without documented evidence of hypogonadism. The study tracked these matched pairs over a follow up period spanning up to 10 years.

This longitudinal approach allowed the researchers to observe long term cardiovascular trends across the two distinct patient categories. The primary medical coverage noted that this overall risk trend was observed across various racial and ethnic groups, although the exact magnitude varied among them. The statistical outcomes indicate a clear divergence in cardiovascular health between the two matched groups. Men treated without documented evidence of hypogonadism faced a higher reported rate of major adverse cardiovascular events.

The reported rate was 16.53 percent for the undocumented group, compared to 11.83 percent for men treated for confirmed hypogonadism. The published article characterizes this specific difference as a 51 percent higher risk. It is crucial to note that the study compares two groups of testosterone users, rather than comparing testosterone therapy to no therapy at all. The report also details elevated associated risks for other severe medical events within the undocumented group.

The article reports a 90 percent higher risk for all-cause mortality among men without documented evidence. It also details a 23 percent higher risk for ischemic stroke and a 41 percent higher risk for cardiac arrest. Additionally, the group lacking documented evidence showed a 32 percent higher risk for heart failure. These figures highlight the potential severity of bypassing established diagnostic protocols before beginning hormone replacement therapy.

Understanding the limitations of the data is a critical aspect of interpreting this medical research. This was a retrospective observational analysis, meaning the reported associations do not establish that the therapy itself directly caused the adverse outcomes. The study authors explicitly emphasized that their findings demonstrate an association rather than strict causation. Furthermore, the article notes that having no documented evidence is not necessarily equivalent to a confirmed absence of hypogonadism.

Incomplete documentation could easily affect how specific patients were classified during the initial data review. The published article identifies several other factors that limit the interpretation of the findings. The researchers pointed to potential residual confounding variables and the incomplete documentation of hypogonadism as primary limitations. The team also faced limited information regarding specific treatment details like durations, administration doses, patient adherence rates and specific medication formulations.

Medical Guidelines Emphasize Confirmed Deficiencies

The recent data reinforces existing medical frameworks and guides how clinicians should approach hormone therapy moving forward. The study authors recommend strict adherence to guideline-based prescribing to protect long-term patient health. They emphasize the absolute necessity of confirming hypogonadism prior to initiating any form of testosterone treatment. Furthermore, they strongly advise ongoing cardiovascular risk monitoring during the follow up phase for all treated patients.

This aligns with foundational guidance on healthy aging and longevity, which prioritizes objective medical testing over assumed treatments. The distinction between targeted clinical evaluation and broad population testing remains a crucial point for veteran healthcare policy. In September 2026, the Endocrine Society addressed a Defense Health Agency guideline concerning testosterone deficiency in male service members. The Society released a statement pointing directly to its clinical practice guideline on testosterone therapy for men with hypogonadism.

They reiterated their firm position against the population-level screening of asymptomatic men. The Society clearly stated that there is currently insufficient evidence to support routine hormone screening for individuals who do not present clinical symptoms. This shift in focus ensures that medical resources remain dedicated to men presenting with verified deficiencies. Clinical evaluation of specific concerns differs completely from screening an entire population of service members by default.

For veterans focused on maintaining a durable physical foundation, prioritizing proper training and performance often yields better baseline results than seeking off-label interventions. The priority remains establishing a documented medical need before altering the body's natural endocrine function. Clinicians are expected to rely heavily on diagnostic evidence rather than subjective patient requests. When patients utilize evidence led military health information, they build a more resilient approach to their long term physical well being.

As observational research continues to highlight the potential complications of off-label prescribing, how will military healthcare systems and veteran clinics adapt their diagnostic requirements to ensure safer long-term outcomes for patients seeking hormone therapy?

Sources

1. Off label testosterone therapy linked to long term cardiovascular risk study
2. Endocrine Society Statement on the Defense Health Agency's ...